Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Express Scripts
Colorcon
Johnson and Johnson
Moodys

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AF-219

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug AF-219?

AF-219 is an investigational drug.

There have been 14 clinical trials for AF-219. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2015.

The most common disease conditions in clinical trials are Cough, Pulmonary Fibrosis, and Idiopathic Pulmonary Fibrosis. The leading clinical trial sponsors are Afferent Pharmaceuticals, Inc., Celerion, and [disabled in preview].

There are fourteen US patents protecting this investigational drug and one hundred and thirteen international patents.

Recent Clinical Trials for AF-219
TitleSponsorPhase
A Multiple-Dose Pharmacokinetics Study of Three AF-219 FormulationsAfferent Pharmaceuticals, Inc.Phase 1
A 12-Week Study in Subjects With Refractory Chronic CoughAfferent Pharmaceuticals, Inc.Phase 2
An 8-Week Refractory Chronic Cough StudyAfferent Pharmaceuticals, Inc.Phase 2

See all AF-219 clinical trials

Clinical Trial Summary for AF-219

Top disease conditions for AF-219
Top clinical trial sponsors for AF-219

See all AF-219 clinical trials

US Patents for AF-219

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AF-219   Start Trial Methods and compositions for treating diseases and conditions Afferent Pharmaceuticals, Inc. (San Mateo, CA)   Start Trial
AF-219   Start Trial Substituted pyrimidines for treatment of chronic cough, neuronal hypersensitivity underlying chronic cough, neuronal hypersensitivity underlying sub-acute cough and neuronal hypersensitivity underlying acute cough Afferent Pharmaceuticals, Inc. (San Mateo, CA)   Start Trial
AF-219   Start Trial Diaminopyrimidines as P2X.sub.3 and P2X.sub.2/3 antagonists Roche Palo Alto LLC (Palo Alto, CA)   Start Trial
AF-219   Start Trial Process for synthesis of phenoxy diaminopyrimidine derivatives Roche Palo Alto LLC (Palo Alto, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AF-219

Drugname Country Document Number Estimated Expiration Related US Patent
AF-219 European Patent Office 3164132 2034-07-03   Start Trial
AF-219 World Intellectual Property Organization (WIPO) 2016004358 2034-07-03   Start Trial
AF-219 Australia 2014308606 2033-08-23   Start Trial
AF-219 Canada 2921395 2033-08-23   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Dow
Moodys
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.